Teva Pharma Files 8-K on Operations & Financials

TL;DR

Teva dropped an 8-K detailing its financials and operations - check it for the latest numbers.

AI Summary

Teva Pharmaceutical Industries Ltd. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition, and also including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This filing signals that Teva Pharmaceutical Industries Ltd. is providing updated operational and financial information to the public, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of operational and financial information, not indicating any immediate adverse events.

Key Players & Entities

• TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
• November 6, 2024 (date) — Date of Report

FAQ

Filing Documents

• f8k_110624.htm (8-K) — 15KB
• exh_991.htm (EX-99.1) — 398KB
• 0001171843-24-006034.txt ( ) — 644KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_110624_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference. The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Document 99.1 Teva Reports 2024 Third Quarter Financial Results 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: November 6, 2024 By: /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR